SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Sartorius Stedim Biotech S.A. (SRTOY) trades at a trailing P/E of 833.5. Trailing earnings yield is 0.12%. PEG 18.77.
Criteria proven by this page:
- VALUE (15/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 833.5); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY 0.12%); PEG > 2.0 means the stock is expensive even after accounting for growth (PEG 18.77).
- PEG Ratio 18.77 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 0.12% — below bond yields — investors are paying a premium for expected growth rather than current earnings.
Overall SharesGrow Score: 44/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
15/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SRTOY
Valuation Multiples
P/E (TTM)833.5
Forward P/EN/A
PEG Ratio18.77
Forward PEGN/A
P/B Ratio0.00
P/S Ratio73.96
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.03
Book Value / Share$0.00
Revenue / Share$0.29
FCF / Share$0.00
Yields & Fair Value
Earnings Yield0.12%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.02 |
$1.05B |
$153.68M |
14.6% |
| 2017 |
$0.02 |
$1.08B |
$161.09M |
14.9% |
| 2018 |
$0.02 |
$1.21B |
$208.05M |
17.2% |
| 2019 |
$0.03 |
$1.44B |
$234.57M |
16.3% |
| 2020 |
$0.04 |
$1.91B |
$335.93M |
17.6% |
| 2021 |
$0.05 |
$2.89B |
$414.4M |
14.4% |
| 2022 |
$0.10 |
$3.49B |
$876.1M |
25.1% |
| 2023 |
$0.03 |
$2.78B |
$309.7M |
11.2% |
| 2024 |
$0.02 |
$2.78B |
$175.1M |
6.3% |
| 2025 |
$0.03 |
$2.85B |
$255.12M |
9% |
